PARIS SANS, MARTA
@salutsantjoan.cat
GENERAL AND DIGESTIVE SURGERY DEPARTMENT
Salut Sant Joan Reus - Baix Camp
RESEARCH, TEACHING, or OTHER INTERESTS
Surgery, Medicine, Anatomy, Nutrition and Dietetics
Scopus Publications
Scopus Publications
Andrea Jiménez-Franco, Helena Castañé, Cristian Martínez-Navidad, Cristina Placed-Gallego, Anna Hernández-Aguilera, Salvador Fernández-Arroyo, Iris Samarra, Marta Canela-Capdevila, Meritxell Arenas, Antonio Zorzano,et al.
Elsevier BV
Helena Castañé, Andrea Jiménez-Franco, Cristian Martínez-Navidad, Cristina Placed-Gallego, Vicente Cambra-Cortés, Adelina-Miruna Perta, Marta París, Daniel del Castillo, Meritxell Arenas, Jordi Camps,et al.
MDPI AG
Paraoxonase-1 (PON1) is an antioxidant enzyme associated with high-density lipoproteins (HDL). Reduced serum PON1 activity is found in diseases marked by oxidative stress and inflammation, but its role in obesity remains unclear. This study investigated PON1 activities and concentrations in morbidly obese individuals and explored the impacts of the genetic polymorphism PON1 rs662 and non-alcoholic fatty liver disease on enzymatic properties. We recruited 1349 morbidly obese patients undergoing bariatric surgery and 823 non-obese volunteers. PON1-related variables, including arylesterase, paraoxonase, and lactonase activities and PON1 concentrations, were examined. Our results showed that morbidly obese individuals exhibited higher PON1 concentrations but lower enzymatic activities than non-obese individuals. We observed inverse associations of arylesterase and paraoxonase activities with waist circumference (rho = −0.24, p < 0.001, and rho = −0.30, p < 0.001, respectively) and body mass index (rho = −0.15, p = 0.001, and rho = −0.23, p < 0.001), as well as direct associations of arylesterase, paraoxonase, and lactonase activities with HDL cholesterol (rho = 0.11, p = 0.005, rho = 0.20, p < 0.001, and rho = 0.20, p < 0.001). No significant differences were observed regarding metabolic syndrome, type 2 diabetes mellitus, hypertension, dyslipidemia, rs662 polymorphism allele frequencies, or the diagnosis of non-alcoholic steatohepatitis. Nevertheless, correlations were found between certain PON1-related variables, steatosis, and ballooning. In conclusion, changes in PON1-related variables in morbidly obese patients are dependent on the disease itself and HDL levels. The relationships between these variables and specific liver histological changes raise intriguing questions for consideration in future studies.
Andrea Barrientos-Riosalido, Laia Bertran, Mercè Vilaró-Blay, Carmen Aguilar, Salomé Martínez, Marta Paris, Fàtima Sabench, David Riesco, Jessica Binetti, Daniel Del Castillo,et al.
MDPI AG
This study’s objective was to assess the involvement of olfactomedin 2 (OLFM2), a secreted glycoprotein related to lipid metabolism regulation, in nonalcoholic fatty liver disease (NAFLD) mediated by the adipose-tissue–liver axis. OLFM2 mRNA expression was analyzed in subcutaneous (SAT) and visceral (VAT) adipose tissue by RT–qPCR. The cohort included women with normal weight (n = 16) or morbid obesity (MO, n = 60) who were subclassified into normal liver (n = 20), simple steatosis (n = 21), and nonalcoholic steatohepatitis (NASH, n = 19) groups. The results showed that OLFM2 expression in SAT was enhanced in MO individuals and in the presence of NAFLD. Specifically, OLFM2 expression in SAT was increased in mild and moderate degrees of steatosis in comparison to the absence of it. Moreover, OLFM2 expression in SAT was negatively correlated with interleukin-6 levels. On the other hand, OLFM2 expression in VAT decreased in the presence of NASH and exhibited a positive correlation with adiponectin levels. In conclusion, OLFM2 in SAT seems to be implicated in hepatic lipid accumulation. Additionally, since we previously suggested the possible implication of hepatic OLFM2 in NAFLD progression, now we propose a possible interaction between the liver and SAT, reinforcing the potential implication of this tissue in NAFLD development.
Fàtima Sabench, Laia Bertran, Margarita Vives, Marta París, Carmen Aguilar, Salomé Martínez, Jessica Binetti, Monica Real, Alja Alibalic, Cristóbal Richart,et al.
Springer Science and Business Media LLC
Noemí Cabré, Fedra Luciano-Mateo, Douglas J. Chapski, Gerard Baiges-Gaya, Salvador Fernández-Arroyo, Anna Hernández-Aguilera, Helena Castañé, Elisabet Rodríguez-Tomàs, Marta París, Fàtima Sabench,et al.
MDPI AG
The surgically induced remission of liver disease represents a model to investigate the signalling processes that trigger the development of nonalcoholic steatohepatitis with the aim of identifying novel therapeutic targets. We recruited patients with severe obesity with or without nonalcoholic steatohepatitis and obtained liver and plasma samples before and after laparoscopic sleeve gastrectomy for immunoblotting, immunocytochemical, metabolomic, transcriptomic and epigenetic analyses. Functional studies were performed in HepG2 cells and primary hepatocytes. Surgery was associated with a decrease in the inflammatory response and revealed the role of mitogen-activated protein kinases. Nonalcoholic steatohepatitis was associated with an increased glutaminolysis-induced production of α-ketoglutarate and the hyperactivation of mammalian target of rapamycin complex 1. These changes were crucial for adenosine monophosphate-activated protein kinase/mammalian target of rapamycin-driven pathways that modulated hepatocyte survival by coordinating apoptosis and autophagy and affected methylation-related epigenomic remodelling enzymes. Hepatic transcriptome signatures and differentially methylated genomic regions distinguished patients with and without steatohepatitis. Our results suggest that the increased glutaminolysis-induced α-ketoglutarate production and the mammalian target of rapamycin complex 1 dysregulation play a crucial role in the inefficient adaptive responses leading to steatohepatitis in obesity.
Anna Hernández-Aguilera, Núria Casacuberta, Helena Castañé, Montserrat Fibla, Salvador Fernández-Arroyo, Isabel Fort-Gallifa, Marta París, Fàtima Sabench, Daniel Del Castillo, Gerard Baiges-Gaya,et al.
Springer Science and Business Media LLC
Noemí Cabré, Míriam Gil, Núria Amigó, Fedra Luciano-Mateo, Gerard Baiges-Gaya, Salvador Fernández-Arroyo, Elisabet Rodríguez-Tomàs, Anna Hernández-Aguilera, Helena Castañé, Marta París,et al.
Springer Science and Business Media LLC
AbstractPatients with morbid obesity frequently present non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) associated with pro-atherogenic alterations. Laparoscopic sleeve gastrectomy (LSG) is an effective treatment for weight reduction, and for the remission of hepatic alterations. Using 1H-nuclear magnetic resonance (1H-NMR), we investigated the effects of LSG on lipoprotein and glycoprotein profile in patients with morbid obesity and liver disease. We included 154 patients with morbid obesity (49 non-NASH, 54 uncertain NASH, 51 definite NASH). A blood sample was obtained before surgery and, in patients with definite NASH, one year after surgery. Patients with NASH had increased concentrations of medium and small VLDL particles, VLDL and IDL cholesterol concentrations, IDL, LDL, and HDL triglyceride concentrations, and elevated glycoprotein levels. These changes were more marked in patients with type 2 diabetes mellitus. LSG produced significant decreases in the concentration of VLDL particles, VLDL cholesterol and triglycerides, an increase in the concentration LDL particles and LDL cholesterol concentrations, and a decrease in protein glycation. We conclude that patients with obesity and NASH had significant alterations in circulating levels of lipoproteins and glycoproteins that were associated with the severity of the disease. Most of these changes were reversed post-LSG.
Beatriz Villar, Laia Bertran, Carmen Aguilar, Jessica Binetti, Salomé Martínez, Fàtima Sabench, Monica Real, David Riesco, Marta París, Daniel Del Castillo,et al.
MDPI AG
Recent studies suggest a link between pro-neurotensin (pro-NT) and nonalcoholic fatty liver disease (NAFLD), but the published data are conflicting. Thus, we aimed to analyze pro-NT levels in women with morbid obesity (MO) and NAFLD to investigate if this molecule is involved in NAFLD and liver lipid metabolism. Plasma levels of pro-NT were determined in 56 subjects with MO and 18 with normal weight (NW). All patients with MO were subclassified according to their liver histology into the normal liver (NL, n = 20) and NAFLD (n = 36) groups. The NAFLD group had 17 subjects with simple steatosis (SS) and 19 with nonalcoholic steatohepatitis (NASH). We used a chemiluminescence sandwich immunoassay to quantify pro-NT in plasma and RT-qPCR to evaluate the hepatic mRNA levels of several lipid metabolism-related genes. We reported that pro-NT levels were significantly higher in MO with NAFLD than in MO without NAFLD. Additionally, pro-NT levels were higher in NASH patients than in NL. The hepatic expression of lipid metabolism-related genes was found to be altered in NAFLD, as previously reported. Additionally, although pro-NT levels correlated with LDL, there was no association with the main lipid metabolism-related genes. These findings suggest that pro-NT could be related to NAFLD progression.
Carmen Balagué, Sonia Fernández-Ananín, Ainitze Ibarzabal, Marta París, Ramón Vilallonga, José Julián Puche, and Juan Carlos Ruiz de Adana
Elsevier BV
Carmen Balagué, Sonia Fernandez-Ananín, Ainitze Ibarzabal, Marta París, Ramón Vilallonga, José Julian Puche, and Juan Carlos Ruiz de Adana
Elsevier BV
Noemí Cabré, Fedra Luciano‐Mateo, Gerard Baiges‐Gayà, Salvador Fernández‐Arroyo, Elisabet Rodríguez‐Tomàs, Anna Hernández‐Aguilera, Marta París, Fàtima Sabench, Daniel Del Castillo, José López‐Miranda,et al.
Wiley
SummaryBackgroundObesity can influence hepatic mitochondrial function, and cause non‐alcoholic steatohepatitis (NASH). Diagnosis and follow‐up rely on invasive liver biopsy so blood‐based markers are urgently required.AimTo investigate whether values of circulating metabolites from energy and one‐carbon (1‐C) metabolism may: (a) reflect hepatic mitochondrial flexibility failure and (b) act as NASH biomarkers.MethodsPatients with severe obesity undergoing bariatric surgery (n = 270) were investigated using quantitative targeted plasma metabolomics. Comparisons were with non‐obese controls without liver disease (n = 50). Obese patients with NASH (n = 53) and without NASH (n = 130) representing extreme groups of liver disease were assessed to test the diagnostic ability of the measured circulating metabolites. Paired liver biopsy and plasma samples from NASH patients were available 1 year post‐surgery and were evaluated to monitor metabolomic changes with liver damage resolution.ResultsWe identified correlations between human liver metabolism and obesity. High‐plasma α‐ketoglutarate (α‐KG) and lactate concentrations in NASH patients indicating citric acid cycle replenishment via glutaminolysis might also be a crucial point in NASH onset. Plasma measurements of α‐KG, β‐hydroxybutyrate, pyruvate and oxaloacetate reduced the uncertainty in clinical diagnosis of NASH [area under receiver operating characteristic curve (AUC) of 0.826] and predicted NASH resolution without ambiguity (AUC of 0.999).ConclusionChanges in plasma mitochondrial metabolites appear to be associated with NASH. These metabolic responses may be dynamically remodelled following resolution of liver damage through massive weight loss.
Noemí Cabré, Fedra Luciano-Mateo, Salvador Fernández-Arroyo, Gerard Baiges-Gayà, Anna Hernández-Aguilera, Montserrat Fibla, Raul Fernández-Julià, Marta París, Fàtima Sabench, Daniel Del Castillo,et al.
Elsevier BV
A Cabrera, M Vives, A Molina, M París, E Raga, A Sánchez, F Sabench, and D. Del Castillo
Springer Science and Business Media LLC
M. Vives, A. Molina, M. Danús, E. Rebenaque, S. Blanco, M. París, A. Sánchez, F. Sabench, and D. Del Castillo
Springer Science and Business Media LLC
Fàtima Sabench Pereferrer, Alicia Molina López, Margarida Vives Espelta, Esther Raga Carceller, Santiago Blanco Blasco, Francisco Buils Vilalta, Marta París Sans, Maria Luisa Piñana Campón, Mercè Hernández González, Antonio Sánchez Marín,et al.
Springer Science and Business Media LLC
Marta París-Sans, Joan Domènech-Calvet, Esther Raga-Carceller, Fàtima Sabench-Pereferrer, and Daniel del Castillo-Déjardin
Elsevier BV